Full history for every metric is available with a Kvantra account
Kunming Longjin Pharmaceutical Co., Ltd. (002750.SZ)
Key financial summary
Financials in CNY| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | CNY m | 275 | 254 | 703 | 123 | 87 | 66 | 46 |
| Operating profit | CNY m | -44 | -43 | |||||
| Net profit | CNY m | -23 | 12 | -7 | -56 | -71 | -41 | -41 |
| EPS reported | CNY | -0.10 | -0.10 | |||||
| Operating cashflow per share | CNY | -0.09 | -0.09 | |||||
| Capex per share | CNY | 0.03 | 0.03 | |||||
| FCF per share | CNY | -0.11 | -0.11 | |||||
| Free cash flow | CNY m | -45 | -57 | |||||
| Net debt | CNY m | -294 | -270 | |||||
| Book value equity | CNY m | 470 | 464 | |||||
| Book value per share | CNY | 1.17 | 1.16 | |||||
| Number of shares | m | 400.42 | 399.99 | |||||
| DPS (TTM paid) | CNY | 0.00 | 0.00 |
Financial summary
Financials in CNY| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 1.86 | 0.51 | |||||
| P/S LTM | x | 13.19 | 5.14 | |||||
| P/FCF LTM | x | -19.52 | -4.13 | |||||
| EV/EBITDA LTM | x | -21.61 | 1.43 | |||||
| EV/Sales LTM | x | 9.30 | -0.74 | |||||
| Earnings Yield LTM | % | -4.73% | -17.54% | |||||
| FCF Yield | % | -5.12% | -24.19% | |||||
| Quality | ||||||||
| ROE | % | -8.81% | -8.44% | |||||
| ROIC | % | -8.36% | -8.36% | |||||
| Operating margin | % | -66.21% | -66.21% | |||||
| Gross margin | % | 40.71% | 40.71% | |||||
| FCF/Sales | % | -67.59% | -67.59% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -23.25% | -49.71% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.02% | 0.00% | |||||
| Dividend Growth | % | - | - | |||||
| Payout Ratio | % | -0.41% | -0.43% | |||||
| FCF/Debt | x | -15.22 | -31.52 | |||||
| Net Debt/EBITDA | x | 9.05 | 9.05 | |||||
| EBIT/Net interest | x | -685.80 | -685.80 | |||||
| Net debt/market cap | % | -33.54% | -114.39% | |||||
| Net debt/Equity | x | -0.63 | -0.58 | |||||
| Gross debt/equity | x | 0.01 | 0.00 | |||||
Company overview
Kunming Longjin Pharmaceutical Co., Ltd., based in China, specializes in the research, manufacturing, and commercialization of a diverse array of pharmaceutical products. Their offerings span from naturally derived botanical drugs to chemical compounds presented as freeze-dried powder injections. The company's comprehensive portfolio includes traditional Chinese medicines, biochemical and synthetic chemical pharmaceuticals, along with treatments for cardiovascular, cerebrovascular, and digestive system disorders. Additionally, they provide immunological agents, first aid supplies, essential vitamins, minerals, and both enteral and parenteral nutritional solutions. Beyond its core pharmaceutical business, the firm has diversified into the cultivation of industrial hemp. Established in 1996, Kunming Longjin Pharmaceutical maintains its headquarters in Kunming, China.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Kunming Longjin Pharmaceutical Co., Ltd. (002750.SZ)
Kunming Longjin Pharmaceutical Co., Ltd., based in China, specializes in the research, manufacturing, and commercialization of a diverse array of pharmaceutical products. Their offerings span from naturally derived botanical drugs to chemical compounds presented as freeze-dried powder injections. The company's comprehensive portfolio includes traditional Chinese medicines, biochemical and synthetic chemical pharmaceuticals, along with treatments for cardiovascular, cerebrovascular, and digestive system disorders. Additionally, they provide immunological agents, first aid supplies, essential vitamins, minerals, and both enteral and parenteral nutritional solutions. Beyond its core pharmaceutical business, the firm has diversified into the cultivation of industrial hemp. Established in 1996, Kunming Longjin Pharmaceutical maintains its headquarters in Kunming, China.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free